To conduct clinical trial studies for AML and MM adoptive cell therapy by the CAR T cell, Neeson et al. [135] engineered the CD28-CD3z-LeY CAR T cell by using the autologous T cells based on LeY-T ex vivo transduction and expansion protocol. This evidence concerns the gene CD247 and acute myeloid leukemia.